Advanced Non-Small Cell Lung Cancer Clinical Trial
Official title:
Phase II Study of Nimotuzumab Plus Docetaxel in Chemotherapy-refractory/Resistant Patients With Advanced Non-small-cell Lung Cancer
Nimotuzumab is a humanized monoclonal anti-body targeting the epidermal growth factor receptor (EGFR). Clinical trials are ongoing globally to evaluate nimotuzumab in different indications. Nimotuzumab has demonstrated a unique clinical profile, where anti-tumor activity was observed in absence of severe skin, renal, gastrointestinal mucosa toxicities commonly associated with EGFR-targeting antibodies. Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in many countries. The investigators compared docetaxel plus nimotuzumab with docetaxel alone in chemotherapy-refractory/resistant patients with advanced EGFR-positive non-small-cell lung cancer to assess the efficacy and safety.
Status | Terminated |
Enrollment | 30 |
Est. completion date | August 2015 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Histological/cytological confirmed Non-small cell lung cancer 2. EGFR expression is positive (Immunohistochemistry) 3. Locally advanced or advanced NSCLC patients(Stage IIIb \ IV) 4. Patients must have had progressive disease after only one prior chemotherapy regimen.This regimen must have been platinum-based.(For the patients who received new adjuvant chemotherapy or adjuvant chemotherapy, only disease free survival within 9 months will be eligible to enrollment). 5. The last dose of chemotherapy must be finished at least 3 weeks before the study, the acute toxicity of chemotherapy must be recovery. 6. The patients previously received radiotherapy could be recruited. (bone marrow influenced by radiotherapy should be less than 25% of the total quantity of general bone marrow ,and the patients didn't receive the whole pelvis radiation, last radiotherapy must be finished at least 4 weeks before the enrollment. ) 7. Patients with at least one tumor lesion that can accurately be measured by magnetic resonance imaging, or computed tomography in at least one dimension with longest diameter to be recorded as = 20 mm using conventional techniques or = 10 mm with spiral CT. 8. ECOG performance status 0-2. 9. Life expectancy = 12 weeks. 10. Adequate organic function must be according with the following: - Barrow: Absolute neutrophil count = 1.5×109/L, platelet count = 100×109/L, Haemoglobin = 90g/L; - Liver function: BIL = 1.5 x ULN, ALP, AST and ALT= 3x ULN or = 5 ULN (Liver metastasis); - Renal function: Ccr = 45ml/min; 11. No history of clinically significant or uncontrolled cardiac disease, normal electrocardiogram(ECG). 12. Use of an effective contraceptive method for patients of both genders during study and after the end of 3 months, female subjects must be non breast feeding period and serum or urine pregnancy test should be negative. 13. Signed informed consent and submit to the organization of research Exclusion Criteria: 1. Brain metastasis and with symptom 2. Previously treatment regimen including:Docetaxel, anti EGFR monoclonal antibody,anti-angiogenesis targeted medicine,small molecule tyrosine kinase inhibitor(TKIs) 3. Receiving other anti-cancer medicine treatment during the study 4. Uncontrolled pleural effusion?seroperitoneum?pericardial effusion 5. Serious illness or other malignancies diagnosed within the past five years. 6. Patients with any serious active infection 7. The second primary malignant tumor 8. Serious accompanying disease would influenced the study (such as cardiac disease,Diabetes mellitus etc) 9. Contraindication of hormone therapy 10. Previous definable peripheral neuropathy and with symptom 11. Do not sign informed consent form |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing Cancer Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Biotech Pharmaceutical Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Median Survival Time | 12 months | No | |
Secondary | Disease control rate | 12 months | No | |
Secondary | Time to progression | 12 months | No | |
Secondary | Safety of the Nimotuzumab and docetaxel (NCI CTC3.0) | 12 months | Yes | |
Secondary | Quality of life before and after the treatment (QLQ-C30) | 12 months | No | |
Secondary | Analysis EGFR expression, EGFR mutation and amplification, K-ras mutation in the tumor tissues | 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04263051 -
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05489731 -
VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01240447 -
Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
|
Phase 2 | |
Completed |
NCT00737867 -
Vinorelbine/Gemcitabine Versus Vinorelbine/Carboplatin in Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT05504278 -
Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
|
Phase 1 | |
Recruiting |
NCT05482568 -
A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06043973 -
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
|
Phase 3 | |
Completed |
NCT00948675 -
Study of Participants With Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03681483 -
RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer
|
Phase 1 | |
Terminated |
NCT05001724 -
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
|
Phase 2/Phase 3 | |
Recruiting |
NCT05099172 -
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
|
Phase 1/Phase 2 | |
Recruiting |
NCT02133196 -
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT00874328 -
A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Completed |
NCT00487669 -
Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Active, not recruiting |
NCT03516981 -
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)
|
Phase 2 | |
Recruiting |
NCT03334864 -
Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)
|
||
Terminated |
NCT00783471 -
Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT00330746 -
CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer
|
Phase 2 | |
Completed |
NCT03117335 -
Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT00345059 -
The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
|
Phase 3 |